Rana Lonnen
Managing Director @ Novartis
Rana Lonnen is a Series A investor at Novartis focused on Health Care and Medical. Rana Lonnen is the Managing Director at Novartis. She attended Imperial College London.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Rana Lonnen invests in
Stages Rana Lonnen invests in
Countries Rana Lonnen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 8 (67%)
- Medical 4 (33%)
- Biotechnology 4 (33%)
- Big Data 2 (17%)
- Software 2 (17%)
Stage
- Series A 4 (33%)
- Series B 3 (25%)
- Series C 3 (25%)
- Venture - Series Unknown 1 (8%)
Country
- United States 7 (58%)
- France 1 (8%)
- Germany 1 (8%)
- Singapore 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Yseop
|
Yseop is an artificial intelligence enterprise software on the market, which automatically writes (or speaks) in intelligent and non-repetitive text, both in English and a variety of other languages, just like a human being, but at a speed of over a thousand pages per second. Using a patented enterprise software based on Artificial Intelligenceand Natural Language Generation, Yseop boosts the performance of business teams by automating tasks such as lead generation, up-selling, cross-selling as well as by writing prep-to-meeting reports, post meeting summaries, personalized proposals, and customer intelligence executive summaries.Yseop’s solution dramatically reduces the cost of sales and makes sales and marketing teams more efficient. With Yseop, a company’s sales team can spend more time on customer interactions and less time on administrative tasks in order to close business faster.Yseop is able to deliver its technology as a SaaS or as an annual term license hosted on a company’s servers. Currently, Yseop is able to generate text in English, German, Dutch, French, Spanish, Japanese. | Venture - Series Unknown / Dec 05, 2023 | |
|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | |
RxLightning
|
RxLightning is a digital solution for specialty medication access, accelerating patients’ speed to therapy. | $17.5M / Series A / Jun 06, 2023 | |
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | $45M / Series B / Jan 09, 2023 | |
H1.co
|
H1 is an AI-powered platform that helps identify and engage the right doctors for critical workflows across pharma, health plan, health system, and technology companies. At the core of the platform is H1’s Doctor Graph—a structured representation of physician identity, expertise, relationships, and behavioral signals, creating a powerful networkeffect as it is continuously enriched by participants across the healthcare ecosystem. Built on one of the world’s largest and most comprehensive global datasets of healthcare professionals, H1 combines deep healthcare data with agentic AI workflows to power critical workflows across drug development, medical and commercial engagement, care navigation, and provider data and network intelligence. Founded in 2017, the company is based in New York, United States. | $23M / Series C / Jun 09, 2022 | |
Koneksa Health
|
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets.Koneksacurrently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States. | $45M / Series C / Feb 07, 2022 | |
Mekonos
|
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development. | $25M / Series A / Nov 09, 2021 | |
Lightship
|
Lightship is a provider of enterprise-level, direct-to-patient clinical research solutions. The company engages patients at home from recruitment through completion and eliminates the hurdles and inefficiencies of traditional approaches. Founded in 2018, Lightship is based in El Segundo, California. | $40M / Series B / Oct 06, 2021 | |
Dopavision
|
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeuticfor myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. | $14.2M / Series A / Jul 14, 2021 | |
| See all 12 investments → | |||
Co-Investors
About Novartis
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Novartis Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Enrico Vanni
Board of Directors
|
|||
Iya Khalil
Global Head of the AI Innovation Center at Novartis
|
|||
José Marcilla
Senior Vice President Head of Southern, Eastern, Russia & Central Europe
|
|||
Justin Rauschkolb
Associate Director, Digital Marketing - HCP Media
|
|||
|
Rana Lonnen
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rana Lonnen invest in?
Rana Lonnen invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rana Lonnen?
Public channels for Rana Lonnen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rana Lonnen last invest?
The most recent investment recorded for Rana Lonnen closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
